SCHEMBL3962619

SCHEMBL3962619

CCNC(=O)NCc1cc2c(ccc3cnn(C[C@H](C)NC(=O)OCc4ccccc4)c32)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.45
HTR2A P28223 3/20 0.45
HTR2B P41595 1/20 0.45
MTNR1A P48039 3/20 0.44
MTNR1B P49286 3/20 0.44
ATM Q13315 1/20 0.38
ITGB3 P05106 3/20 0.37
ITGAV P06756 3/20 0.37
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2D6 P10635 2/20 0.36
MAPT P10636 2/20 0.36
TSHR P16473 2/20 0.36
HPGD P15428 2/20 0.36
PKM P14618 1/20 0.36
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3960946 0.88 HTR2C (0.48) HTR2CHTR2AHTR2BATMALDH1A1
SCHEMBL3967475 0.87 HTR2C (0.49) HTR2CHTR2AHTR2BATM
SCHEMBL3966073 0.86 CYP3A4 (0.41) HTR2CHTR2AHTR2BCYP3A4MAPT
SCHEMBL3965535 0.85 HTR2C (0.45) HTR2CHTR2AHTR2BATMCTSL
SCHEMBL3960316 0.84 HTR2C (0.46) HTR2CHTR2AHTR2BATMMAPT
SCHEMBL3960312 0.84 HTR2C (0.46) HTR2CHTR2AHTR2BATMMAPT
SCHEMBL3962497 0.84 HTR2C (0.46) HTR2CHTR2AHTR2BATM
SCHEMBL3962501 0.84 HTR2C (0.46) HTR2CHTR2AHTR2BATM
SCHEMBL3958249 0.84 HTR2C (0.46) HTR2CHTR2AHTR2BATM
SCHEMBL6253366 0.84 MTNR1A (0.47) HTR2CHTR2AHTR2BMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476687-B2 Substituted furo[2,3-g]indazoles for the treatment of glaucoma ALCON, INC. (CH) 2009-01-13 US disclosed
US-20090012291-A1 SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2009-01-08 US disclosed
US-20070135430-A1 Substituted furo[2,3-g]indazoles for the treatment of glaucoma ALCON, INC. (CH) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135430-A1 Substituted furo[2,3-g]indazoles for the treatment of glaucoma PTGIS, PTGIR, PTGS2 HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885
US-20090012291-A1 SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA PTGIS, PTGIR, PTGS2 HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.